SOUTH SAN FRANCISCO, Calif., May 8, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) today announced that the company will present at the Credit Suisse Antibody Conference, to be held in New York City on May 10, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
Company Presentation: When: Friday, May 10, 2013, 10:30AM Eastern Time Where: One Madison Avenue at 24th Street, New York, NY
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.
Contact: Jeffrey H. Cooper Chief Financial Officer KaloBios Pharmaceuticals, Inc. (650) 243-3146 firstname.lastname@example.org
Media Contact: Joan E. Kureczka Kureczka/Martin Associates Tel: (415) 821-2413 Mobile: (415) 690-0210 Joan@Kureczka-Martin.com
SOURCE KaloBios Pharmaceuticals, Inc.